If we are successful in getting this pathway to biosimilars moving then my fear is with a product sitting on the market that could cost 30 percent less we are going to be behind th...
We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting presc...
This increased cost is born by our healthcare system as a whole, but more specifically by patients as more and more insu...
I hope that we can talk about that today.
These reductions will result in significant savings to the healthcare system and patients as the biosimilar market matur...
Thank you, Mr. Chairman.
We talked about the certainty that the industry needs to start populating the field with more biosimilars.
I know this is an issue that doesn't necessarily fit natural to Congress to be funding physician and provider education,...
If we get a whole rash of State laws that erect barriers it doesn't really matter what education you do if the law preve...
It took us a long time to educate both providers and patients about chemical generics.
I think that there is a potentially really significantly high cost to the United States compared to what I would suggest...